THE COL1A1 1997C/A (RS1107946) GENE POLYMORPHISM IN OSTEOPOROSIS ASSOCIATED WITH CARDIORENAL SYNDROME
DOI:
https://doi.org/10.5281/zenodo.23878408Keywords:
chronic kidney disease, osteoporosis, COL1A1 gene, rs1107946, chronic heart failure, cardiorenal syndromeAbstract
Background. Bone strength depends on the organic matrix as well as on mineral content, and type I collagen is its principal protein. The COL1A1 gene encodes the alpha-1 chain of this collagen, and promoter variants alter transcription and the ratio of alpha-1 to alpha-2 chains, thereby affecting bone quality independently of bone mineral density. Aim. In chronic kidney disease (CKD), the bone matrix is already compromised by mineral dysregulation and secondary hyperparathyroidism, while concomitant chronic heart failure (CHF) adds neurohumoral, inflammatory and nutritional burdens. Whether a matrix-related genetic variant becomes phenotypically apparent in this setting has not yet been examined. Materials and Methods. The study enrolled 196 subjects divided into three groups: patients with CHF, CKD and osteoporosis (n = 52); patients with CKD and osteoporosis without clinically significant CHF (n = 48); and healthy volunteers comprising the control group (n = 96). The study assessed calcium-phosphorus metabolism, intact parathyroid hormone, 25-hydroxyvitamin D, serum creatinine, estimated glomerular filtration rate and N-terminal pro-Btype natriuretic peptide. The COL1A1 1997C/A polymorphism (rs1107946) was genotyped by polymerase chain reaction with restriction fragment length polymorphism analysis. Odds ratios and their 95% confidence intervals were calculated using the Woolf method, and statistical significance was assessed using the two-sided Fisher exact test. Results. Genotype distributions conformed to Hardy–Weinberg equilibrium in all groups. The minor A allele was significantly more frequent in both patient groups than in the control group, and the association demonstrated a graded pattern: it was stronger in the group with CHF than in the group without CHF, with a statistically significant difference between the two patient groups. Moreover, heterozygous C/A genotype carriage was overrepresented to almost the same extent in both patient groups, whereas A/A homozygosity was overrepresented only in the group with CHF. In the absence of CHF, the frequency of the A/A genotype did not differ significantly from that in the control group. Conclusion. The A allele of the COL1A1 1997C/A polymorphism acts as a risk marker for osteoporosis in CKD, irrespective of cardiac status, whereas its homozygous form is specifically associated with the cardiorenal phenotype. Consequently, genotype provides an additional, non-fluctuating layer of information alongside mineral indices already used to predict fracture risk in CKD. These findings warrant replication in larger regional cohorts.References
1. Cichocka, E., Górczyńska-Kosiorz, S. B., Niemiec, P., Trautsolt, W., & Gumprecht, J. (2025). The impact of selected COL1A1 and COL1A2 gene polymorphisms on bone mineral density and the risk of metabolic diseases in postmenopausal women. Int J Mol Sci, 26. https://doi.org/10.3390/ijms26114981
2. Goto, N. A., Weststrate, A. C. G., Oosterlaan, F. M., et al. (2020). The association between chronic kidney disease, falls, and fractures: a systematic review and meta-analysis. Osteoporos Int, 31, 13–29. https://doi.org/10.1007/s00198-019-05190-5
3. Haarhaus, M., Jørgensen, H. S., Bacchetta, J., et al. (2026). Bone turnover markers in the management of CKDassociated osteoporosis: a European consensus. Nephrol Dial Transplant, 41, 1357–1375. https://doi.org/10.1093/ndt/gfag033
4. Inker, L. A., Eneanya, N. D., Coresh, J., et al. (2021). New creatinine- and cystatin C-based equations to estimate GFR without race. N Engl J Med, 385, 1737–1749. https://doi.org/10.1056/NEJMoa2102953
5. Jančuška, A., Kužma, M., Králik, R., et al. (2025). Skeletal changes and vascular calcifications in chronic kidney disease: two connected cups. Bratisl Med J, 126, 637–648. https://doi.org/10.1007/s44411-025-00087-8
6. Jin, H., Evangelou, E., Ioannidis, J. P. A., & Ralston, S. H. (2011). Polymorphisms in the 5′ flank of COL1A1 gene and osteoporosis: meta-analysis of published studies. Osteoporos Int, 22, 911–921. https://doi.org/10.1007/s00198-010-1364-5
7. Kampka, Z., Czapla, D., Wojakowski, W., Stanek, A., & Vitamin, D. (2025). supplementation in heart failure – confusion without a cause?. Nutrients, 17. https://doi.org/10.3390/nu17111839
8. Ketteler, M., Evenepoel, P., Holden, R. M., et al. (2025). Chronic kidney disease–mineral and bone disorder: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int, 107, 405–423. https://doi.org/10.1016/j.kint.2024.11.013
9. Kotrych, K., Wojtuń, M., Górska, A., et al. (2025). The influence of clinical factors and genetic variants of COL1A1 and TNFRSF11B on bone mineral density in postmenopausal women. Int J Mol Sci, 26. https://doi.org/10.3390/ijms26188894
10. LeBoff, M. S., Greenspan, S. L., Insogna, K. L., et al. (2022). The clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int, 33, 2049–2102. https://doi.org/10.1007/s00198-021-05900-y
11. Levin, A., Ahmed, S. B., Carrero, J. J., et al. (2024). Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease: known knowns and known unknowns. Kidney Int, 105, 684–701. https://doi.org/10.1016/j.kint.2023.10.016
12. Liu, Y., Zhang, Z. X., Fu, C. S., et al. (2025). Association of aberrant mineral metabolic markers with fracture risk in chronic kidney disease: a comprehensive meta-analysis. BMC Nephrol, 26, 12882–025. https://doi.org/10.1186/s12882-025-03992-w
13. Mann, V., Hobson, E. E., Li, B., et al. (2001). A COL1A1 Sp1 binding site polymorphism predisposes to osteoporotic fracture by affecting bone density and quality. J Clin Invest, 107, 899–907. https://doi.org/10.1172/JCI10347
14. McDonagh, T. A., Metra, M., Adamo, M., et al. (2023). 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J, 44, 3627–3639. https://doi.org/10.1093/eurheartj/ehad195
15. Mo, C., Ke, J., Zhao, D., et al. (2020). Role of the renin–angiotensin–aldosterone system in bone metabolism. J Bone Miner Metab, 38, 772–779. https://doi.org/10.1007/s00774-020-01132-y
16. Moustaki, M., Paschou, S. A., Palioura, E., et al. (2026). Chronic kidney disease: from mineral dysregulation to bone and cardiovascular disease. J Endocrinol Invest, 40618–026. https://doi.org/10.1007/s40618-026-02955-8
17. Nadirova, Yu. I., & Bobosharipov, F. G. (2024). Kliniko-diagnosticheskie aspekty rannego razvitiya osteoporoza pri khronicheskoi serdechnoi nedostatochnosti [Clinical and diagnostic aspects of the early development of osteoporosis in chronic heart failure]. International Scientific-Online Conference.
18. Nadirova, Yu., & Jabbarov, O. (2023). Faktory riska snizheniya prochnosti kosti i perelomov pri KhBP [Risk factors for reduced bone strength and fractures in chronic kidney disease]. Obrazovanie, nauka i innovatsionnye idei v mire, 21, 97–104.
19. Nakagawa, Y., & Komaba, H. (2024). Roles of parathyroid hormone and fibroblast growth factor 23 in advanced chronic kidney disease. Endocrinol Metab (Seoul), 39, 407–415. https://doi.org/10.3803/
20. Paschalis, E. P., Gamsjaeger, S., Hassler, N., et al. (2026). Bone organic matrix quality indices associate with fragility fracture occurrence independently of bone mineral density values. Osteoporos Int, 00198–026. https://doi.org/10.1007/s00198-026-08182-4
21. Rangaswami, J., Bhalla, V., Blair, J. E., et al. (2019). Cardiorenal syndrome: classification, pathophysiology, diagnosis, and treatment strategies. A scientific statement from the American Heart Association. Circulation, 139. https://doi.org/10.1161/CIR.0000000000000664
22. Rashid, A., Hauge, S. C., Nielsen, B. R., et al. (2026). High prevalence of sarcopenia, osteoporosis and osteosarcopenia in patients with chronic kidney disease compared with healthy controls. Osteoporos Int, 37, 1105–1114. https://doi.org/10.1007/s00198-026-08008-3
23. Spoladore, R., Ciampi, C. M., Ossola, P., et al. (2025). Heart failure and osteoporosis: shared challenges in the aging population. J Cardiovasc Dev Dis, 12. https://doi.org/10.3390/jcdd12020069
24. Verheyen, N., Schmid, J., Kolesnik, E., et al. (2024). Prevalence and prognostic impact of bone disease in chronic heart failure with reduced ejection fraction. ESC Heart Fail, 11, 1730–1738. https://doi.org/10.1002/
25. Xie, P., Liu, B., Zhang, L., et al. (2015). Association of COL1A1 polymorphisms with osteoporosis: a meta-analysis of clinical studies. Int J Clin Exp Med, 8, 14764–14781.
26. Xu, P., Wang, Y., Wu, X., et al. (2024). The COL1A1 rs1800012 polymorphism is associated with osteoporosis or fracture risk: a meta-analysis of 30 studies. Int J Burn Trauma, 14, 148–159. https://doi.org/10.62347/KKAM3344

